Ultra 96: Ultra-High-Throughput Antibody Production Services

Variation in 96 DWP

The Average Titer and Recovery Rate of “Ultra 96” Platform Left histogram shows the average titer of each kind of molecules expressed in 96 DWP at 1 mL scale. Besides, the average recovery rate after one step purification is above 83%. 1503

Recovery Rate (24DWP)

Average 84%

90%

80%

70%

60%

Titer Variation in 96 DWP

50%

Recovery Rate (24DWP)

1 2 3 4 5 6 7 8 9 101112131415161718192021222324

969

Average 84%

90%

1503

80%

50% 50.0% 55.0% 60.0% 65.0% 70.0% 75.0% 80.0% 85.0% 90.0% 95.0% 1 3 5 7 9 11131517192123252729313335373941434547495153555759 Recovery Rate (96DWP) Average 83% 60% 1 2 3 4 5 6 7 8 9 101112131415161718192021222324 50.0% 55.0% 60.0% 65.0% 70.0% 75.0% 80.0% 85.0% 90.0% 95.0% 1 3 5 7 9 11131517192123252729313335373941434547495153555759 Recovery Rate (96DWP) Average 83%

Need original image 70%

595

1013

969

595

mAb

Bi-specific

Bi-specific Fc fusion

Control

mAb

Fc fusion

Case Study: WuXian TM uHTP Platform

For high throughput antibody production, Ultra 96 can maintain high titer even for some AI designed molecules (853 Abs) and the protein after 1 step purification can be enough for any in vitro assay requirement.

853 Antibodies

50 Antibodies

88 His-VHH

60 Antibodies

4

1.5

1.0

5

1.2

0.8

4

3

3.1 mg

0.6

0.9

3

0.52 mg

1.8 mg

2

0.7 g/L

0.4

2

0.6

1

0.2

1

0.3

0.0

0

0

0

96 Well DWP (1 ml/well)

24 Well DWP (3 ml/well)

Learn more: Protein Sciences: uHTP Antibody Production

About WuXi Biologics

WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.

The world’s leading global single-source platform from concept to commercialization.

wuxibiologics.com | info@wuxibiologics.com

3-20-2023

Powered by